DRUG DISCOVERY Inhibitors that activate

被引：65

作者：

Cichowski, Karen ^{[1
]}

Jaenne, Pasi A. ^{[2
]}

机构：

[1] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA

[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

来源：

NATURE | 2010年 / 464卷 / 7287期

关键词：

SQUAMOUS-CELL CARCINOMAS; BRAF;

D O I：

10.1038/464358a

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Inhibitors of RAF enzymes can suppress or activate the same signalling pathway. The details of how this happens provide a cautionary note for those targeting the pathway for anticancer drug discovery.

引用

页码：358 / 359

页数：2

共 9 条

[1] Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers [J].

Adjei, Alex A. ;

Cohen, Roger B. ;

Franklin, Wilbur ;

Morris, Clive ;

Wilson, David ;

Molina, Julian R. ;

Hanson, Lorelei J. ;

Gore, Lia ;

Chow, Laura ;

Leong, Stephen ;

Maloney, Lara ;

Gordon, Gilad ;

Simmons, Heidi ;

Marlow, Allison ;

Litwiler, Kevin ;

Brown, Suzy ;

Poch, Gregory ;

Kane, Katie ;

Haney, Jerry ;

Eckhardt, S. Gail .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) :2139-2146

[2] Keratoacanthomas and Squamous Cell Carcinomas in Patients Receiving Sorafenib [J].

Arnault, Jean Philippe ;

Wechsler, Janine .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) :E59-E61

[3]

Flaherty K, 2009, J CLIN ONCOL, V27

[4] RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth [J].

Hatzivassiliou, Georgia ;

Song, Kyung ;

Yen, Ivana ;

Brandhuber, Barbara J. ;

Anderson, Daniel J. ;

Alvarado, Ryan ;

Ludlam, Mary J. C. ;

Stokoe, David ;

Gloor, Susan L. ;

Vigers, Guy ;

Morales, Tony ;

Aliagas, Ignacio ;

Liu, Bonnie ;

Sideris, Steve ;

Hoeflich, Klaus P. ;

Jaiswal, Bijay S. ;

Seshagiri, Somasekar ;

Koeppen, Hartmut ;

Belvin, Marcia ;

Friedman, Lori S. ;

Malek, Shiva .

NATURE, 2010, 464 (7287) :431-U132

[5] Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF [J].

Heidorn, Sonja J. ;

Milagre, Carla ;

Whittaker, Steven ;

Nourry, Arnaud ;

Niculescu-Duvas, Ion ;

Dhomen, Nathalie ;

Hussain, Jahan ;

Reis-Filho, Jorge S. ;

Springer, Caroline J. ;

Pritchard, Catrin ;

Marais, Richard .

CELL, 2010, 140 (02) :209-221

[6]

Ikenoue T, 2003, CANCER RES, V63, P8132

[7] RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF [J].

Poulikakos, Poulikos I. ;

Zhang, Chao ;

Bollag, Gideon ;

Shokat, Kevan M. ;

Rosen, Neal .

NATURE, 2010, 464 (7287) :427-U126

[8] BRAF mutation predicts sensitivity to MEK inhibition [J].

Solit, DB ;

Garraway, LA ;

Pratilas, CA ;

Sawai, A ;

Getz, G ;

Basso, A ;

Ye, Q ;

Lobo, JM ;

She, YH ;

Osman, I ;

Golub, TR ;

Sebolt-Leopold, J ;

Sellers, WR ;

Rosen, N .

NATURE, 2006, 439 (7074) :358-362

[9] ACTIVATED RAS GENES OCCUR IN HUMAN ACTINIC KERATOSES, PREMALIGNANT PRECURSORS TO SQUAMOUS-CELL CARCINOMAS [J].

SPENCER, JM ;

KAHN, SM ;

JIANG, W ;

DELEO, VA ;

WEINSTEIN, IB .

ARCHIVES OF DERMATOLOGY, 1995, 131 (07) :796-800

← 1 →